



Advances in Ocular Immunology of Diabetes and Related Complications: Mechanisms and Treatments

Guest Editor:

Dr. Kofi Asiedu

School of Optometry & Vision
Science, University of New South
Wales, Sydney, NSW 2052,
Australia

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editor

Corneal neuroimmune features have become a focal point in the study of diabetic neuropathy. Previous research conducted on diabetic chronic kidney disease indicated that it leads to more severe corneal neuroinflammation and greater corneal nerve loss. Certain treatments suggesting the potential regeneration of corneal nerves or amelioration of associated neuroinflammation in diabetes and its complications were explored. However, there are still many unanswered questions in this expanding area of ophthalmic research, necessitating further research. This issue will focus on the mechanisms and treatment of corneal neuroimmune abnormalities in metabolic diseases such as type 1 diabetes, diabetic chronic kidney disease, type 2 diabetes, metabolic syndrome and prediabetes. The issue will also cover the impact of diabetic and non-diabetic medications on corneal neuroimmune features in impaired glycemia. Papers exploring ocular surface and retinal inflammation in diabetes and related complications are also encouraged. This issue will be a collection of original papers and reviews.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)